Definium Therapeutics Completes $805 Million Upsized Public Offering

Source Summary

Hogan Lovells has advised Definium Therapeutics, Inc. Definium Therapeutics, Inc. (Nasdaq: DFTX), a late-stage clinical biopharmaceutical company formerly known as Mind Medicine, has completed an upsized [...]